Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

Cited by (376)

Items 101–200 of 376

1. Modelling olanzapine-induced weight gain in rats
   Esther M. van der Zwaal, Sanna K. Janhunen, Susanne Eva la Fleur, Roger A.H. Adan · 2013 · The International Journal of Neuropsychopharmacology
2. A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis
   Brian J. Miller · 2008 · Journal of Psychiatric Practice
3. The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
   Stefan Leucht, Anna Chaimani, Marc Krause, Johannes Schneider‐Thoma, Dongfang Wang, Shimeng Dong, Myrto T. Samara, Natalie Luise Peter, Maximilian Huhn, Josef Priller et al. · 2022 · The Lancet Psychiatry
4. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain
   Johan Fernø, Kari M. Ersland, I.H. Duus, Ismael González‐García, Kjell Ove Fossan, Rolf Kristian Berge, Vidar M. Steen, Silje Skrede · 2015 · European Neuropsychopharmacology
5. Alternative Delivery Systems for Agents to Treat Acute Agitation: Progress to Date
   Kimberly Nordstrom, Michael H. Allen · 2013 · Drugs
6. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
   Virginia L. Stauffer, Guochen Song, Bruce J. Kinon, Haya Ascher‐Svanum, Lei Chen, Peter D. Feldman, Robert R. Conley · 2011 · Schizophrenia Research
7. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
   Miquel Bioque, Adrián LLerena, Bibiana Cabrera, Gisela Mezquida, António Lobo, Ana María González-Pinto, Covadonga M. Díaz‐Caneja, Iluminada Corripio, Eduardo Jesús Aguilar, Antonio Bulbena et al. · 2015 · The International Journal of Neuropsychopharmacology
8. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
   Diego Novick, Josep Maria Haro, Eléna Perrin, David L. Suarez, João Marques Teixeira · 2009 · European Neuropsychopharmacology
9. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study
   Josep Maria Haro, Diego Novick, David L. Suarez, Mercedes Roca · 2008 · Journal of Psychiatric Research
10. Statistically Significant Increase in Weight Caused by Low‐Dose Quetiapine
    Scott G. Williams, Nima A. Alinejad, Jeannie A. Williams, David F. Cruess · 2010 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
11. Mapping brain-behavior space relationships along the psychosis spectrum
    Jie Lisa Ji, Markus Helmer, Clara Fonteneau, Joshua B. Burt, Zailyn Tamayo, Jure Demšar, Brendan D. Adkinson, Aleksandar Savić, Katrin H. Preller, Flora Moujaes et al. · 2021 · eLife
12. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome
    Netta Dori, Tamar Green, Abraham Weizman, Doron Gothelf · 2015 · Journal of Child and Adolescent Psychopharmacology
13. Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study
    Rafal A.H. Yeisen, Jone Ravndal Bjørnestad, Inge Joa, Jan Olav Johannessen, Stein Opjordsmoen · 2017 · BMC Psychiatry
14. Schizophrenia during Menopausal Transition
    Elizabeth A Crow, Suzanne G. Jasberg · 2016 · Mental Health in Family Medicine
15. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia
    Henry A. Nasrallah, John W. Newcomer, Robert C. Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Srdjan Stankovic, Bernard L. Silverman, Elliot W. Ehrich · 2016 · The Journal of Clinical Psychiatry
16. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
    Priyanka Kolli, Grace Kelley, Marianela Rosales, Justin Faden, Ryan Serdenes · 2023 · Pharmacogenomics and Personalized Medicine
17. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis
    Luis San, Belén Arranz, Víctor Pérez, Gemma Safont, Iluminada Corripio, Nicolas Ramirez, Rosa Dueñas, Enric Álvarez · 2012 · Psychiatry Research
18. Clinical management of comorbid diabetes and psychotic disorders
    Lydia Chwastiak, Oliver Freudenreich, Cenk Tek, Christine L. McKibbin, Jaesu Han, Robert M. McCarron, Brent E. Wisse · 2015 · The Lancet Psychiatry
19. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
    Andrew J. Cutler, Amir H Kalali, Gregory W. Mattingly, Jelena L. Kunovac, Xiangyi Meng · 2013 · CNS Spectrums
20. Antipsychotic medication and social cue recognition in chronic schizophrenia
    David Leland Roberts, David L. Penn, Patrick William Corrigan, Ilya A. Lipkovich, Bruce J. Kinon, Ryan A. Black · 2010 · Psychiatry Research
21. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
    Julia M. Gohlke · 2012 · Frontiers in Psychiatry
22. Neuroprotection: A New Strategy in the Treatment of Schizophrenia
    Jeffrey Alan Lieberman, P.F. Buckley, Diana O. Perkins · 2007 · CNS Spectrums
23. Detecting and Managing Adverse Effects of Antipsychotic Medications
    Donna Ames, Sian M. Carr‐Lopez, Mary A. Gutierrez, Joseph M. Pierre, Jennifer A. Rosen, Susan Shakib, Lynn M. Yudofsky · 2016 · Psychiatric Clinics of North America
24. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
    Cheng Zhang, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao et al. · 2019 · Journal of Psychopharmacology
25. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
    Chris Bushe, Jennifer L Sniadecki, AJ Bradley, Vicki Poole Hoffmann · 2009 · Journal of Psychopharmacology
26. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
    Bill Montgomery, Treuer, Karagianis, Haya Ascher‐Svanum, Harrison · 2012 · Patient Preference and Adherence
27. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
    Christoph Ulrich Correll, Mikkel Højlund, Christine E. Graham, Mark S. Todtenkopf, David McDonnell, Adam Simmons · 2023 · The International Journal of Neuropsychopharmacology
28. Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
    Brian J. Miller, Chelsea M. Bodenheimer, Krystle Crittenden · 2011 · Clinical Psychopharmacology and Neuroscience
29. Evaluation of a multi-element treatment center for early psychosis in the United States
    Sarah R. Uzenoff, David L. Penn, Karen A. Graham, Sylvia Saade, Barbara B. Smith, Diana O. Perkins · 2012 · Social Psychiatry and Psychiatric Epidemiology
30. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
    Henry A. Nasrallah, Ralph Aquila, Yangchun Du, Arielle D. Stanford, Amy Claxton, Peter J. Weiden · 2018 · CNS Spectrums
31. Urinary side effects of psychotropic drugs: A systematic review and metanalysis
    Margherita Trinchieri, G. Perletti, V. Magri, K. Stamatiou, E. Montanari, A. Trinchieri · 2021 · Neurourology and Urodynamics
32. An Epidemiologic Study of Psychotropic Medication and Obesity-Related Chronic Illnesses in Older Psychiatric Patients
    Steve R Kisely, Martha Cox, Leslie Anne Campbell, Charmaine Cooke, David Martin Gardner · 2009 · The Canadian Journal of Psychiatry
33. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis
    Benedicto Crespo‐Facorro, Rocío Pérez‐Iglesias, Ignacio Fernandez Mata, Obdulia Martínez‐García, Víctor Ortiz‐García de la Foz, José María Pelayo‐Terán, Elsa M. Valdizán, José Luis Vázquez‐Barquero · 2011 · Psychopharmacology
34. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
    Xiaofeng Guo, Maosheng Fang, Jinguo Zhai, Bo Wang, Chuanyue Wang, Bin Hu, Xueli Sun, Luxian Lv, Zheng Lu, Cui Ma et al. · 2011 · Psychopharmacology
35. Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study
    Richard Whale, Michael Harris, Gail Kavanagh, Vijitha Wickramasinghe, Christopher Iain Jones, Steven Marwaha, Ketan Dipak Jethwa, Nirmalan Ayadurai, Andrew David Thompson · 2016 · BJPsych Open
36. A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study
    Donald Emile Addington, Alain Labelle, Jayashri Kulkarni, Gordon Johnson, Antony D Loebel, Francine S. Mandel · 2009 · The Canadian Journal of Psychiatry
37. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).
    H. Takeuchi, G. Fervaha, Jimmy Lee, O. Agid, G. Remington · 2016 · Journal of Psychiatric Research
38. Twenty-Four Months of Antipsychotic Treatment in Children and Adolescents With First Psychotic Episode
    Ana Noguera, Patricia Ballesta, Immaculada Baeza, Celso Arango, Elena de la Serna, Ana María González-Pinto, Mara Parellada, Montserrat Graell, Carmen Moreno, Soraya Otero et al. · 2013 · Journal of Clinical Psychopharmacology
39. Unanswered Questions in Schizophrenia Clinical Trials
    John Michael Kane, Stefan Leucht · 2007 · Schizophrenia Bulletin
40. The Psychopharmacology Algorithm Project at the Harvard South Shore Program
    Othman Mohammad, David N. Osser · 2014 · Harvard Review of Psychiatry
41. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
    Cynthia Samtani, Sliwa, Fu, Turkoz, Larry D Alphs · 2012 · Neuropsychiatric Disease and Treatment
42. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials
    Darius Soonawala, Rutger A. Middelburg, Matthias Egger, Jan Paul Vandenbroucke, Olaf M. Dekkers · 2010 · International Journal of Epidemiology
43. The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia
    Julie A. Kreyenbuhl, Deborah R. Medoff, Joseph P. McEvoy, Thomas E. Smith, Ann L. Hackman, Ilana R. Nossel, Lisa B. Dixon, Susan M. Essock, Robert W. Buchanan · 2016 · Psychiatric Services
44. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis
    Srisurapanont, Manit, Likhitsathian, Surinporn, Suttajit, Sirijit, Maneeton, Narong, Maneeton, Benchalak, Oon‐arom, Awirut, Suradom, Chawisa · 2021 · Drug and Alcohol Dependence
45. Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
    Brian A. Millen, Giedra M Campbell, Charles M. Beasley · 2010 · Journal of Psychopharmacology
46. Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
    Jing Huang, Gangrui Hei, Ye Yang, Chenchen Liu, Jingmei Xiao, Yujun Long, Xingjie Peng, Yi Yang, Jingping Zhao, Renrong Wu · 2020 · Frontiers in Pharmacology
47. Examining the effectiveness of antipsychotic medication in first-episode psychosis
    Mark Taylor, Jonathan Cavanagh, Richard Eric Hodgson, Jari Tiihonen · 2012 · Journal of Psychopharmacology
48. Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis
    Veena Kumari · 2010 · Frontiers in Behavioral Neuroscience
49. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol
    Alberto Parabiaghi, Mauro Tettamanti, Barbara D’Avanzo, Angelo Barbato, the GiSAS study group · 2015 · Acta Psychiatrica Scandinavica
50. Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
    Benedicto Crespo‐Facorro, José María Pelayo‐Terán, Jacqueline Mayoral-van Son · 2016 · Neurology and Therapy
51. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial
    Benedicto Crespo‐Facorro, Víctor Ortiz‐García de la Foz, Ignacio Fernandez Mata, Rosa Ayesa‐Arriola, Paula Suárez‐Pinilla, Elsa M. Valdizán, José Luis Vázquez‐Barquero, Rocío Pérez‐Iglesias · 2013 · Schizophrenia Research
52. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year
    Benedicto Crespo‐Facorro, Víctor Ortiz‐García de la Foz, Ignacio Fernandez Mata, Rosa Ayesa‐Arriola, Paula Suárez‐Pinilla, Elsa M. Valdizán, Obdulia Martínez‐García, Rocío Pérez‐Iglesias · 2013 · Psychopharmacology
53. Esquire Trial
    Rafael Gafoor, Sabine Landau, Tom Craig, Thomas Elanjithara, Paddy Power, Philip K. McGuire · 2010 · Journal of Clinical Psychopharmacology
54. Towards a framework for treatment effectiveness in schizophrenia
    Georg Juckel, Andrea de Bartolomeis, Philip A. P. M. Gorwood, Sergey N Mosolov, Luca Pani, Alessandro Rossi, Julio Sanjuán · 2014 · Neuropsychiatric Disease and Treatment
55. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.
    A. Trinchieri, G. Perletti, V. Magri, K. Stamatiou, Margherita Trinchieri, E. Montanari · 2021 · Archivio Italiano di Urologia e Andrologia
56. Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
    Walter Milano, Michele De Rosa, Luca Milano, Anna Capasso · 2013 · The Open Neurology Journal
57. Confirmatory factor analysis of the quality of life scale and new proposed factor structure for the quality of life scale-revised
    Kim T. Mueser, Min Gyu Kim, Jean Addington, Susan R. McGurk, Sarah I. Pratt, Donald Emile Addington · 2016 · Schizophrenia Research
58. Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics
    Mary Coughlin, Catherine Goldie, Joan E. Tranmer, Sarosh Khalid‐Khan, Deborah Tregunno · 2018 · The Canadian Journal of Psychiatry
59. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis
    Chakrapani Balijepalli, Eric Druyts, Michael J. Zoratti, Ping Wu, Salmaan Kanji, Kiran Rabheru, Kevin Yan, Kristian Thorlund · 2018 · Schizophrenia Research and Treatment
60. Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine
    Kluge, Michael, Himmerich, Hubertus, Wehmeier, Peter M., Rummel-Kluge, Christine, Dalal, Mira, Hinze-Selch, Dunja, Kraus, Thomas, Dittmann, Ralf W., Pollmächer, Thomas, Schuld, Andreas · 2012 · Schizophrenia Research
61. Appraising Evidence for Intervention Effectiveness in Early Psychosis: Conceptual Framework and Review of Evaluation Approaches
    Stanley Victor Catts, Brian Ignatius O’Toole, Vaughan J. Carr, Terry J. Lewin, Amanda L. Neil, Meredith Harris, Aaron D. J. Frost, Belinda Crissman, Kathy Eadie, Russell W. Evans · 2010 · Australian & New Zealand Journal of Psychiatry
62. Stability of medication in early psychosis: a comparison between second‐generation and low‐dose first‐generation antipsychotics
    Stein Opjordsmoen, Ingrid S. Melle, Svein Friis, Ulrik Haahr, Jan Olav Johannessen, Tor Ketil Larsen, Bjørn R. Rund, Erik Hertel Simonsen, Per Vaglum, Thomas H. McGlashan · 2009 · Early Intervention in Psychiatry
63. Predictors of ‘all-cause discontinuation’ of initial oral antipsychotic medication in first episode psychosis
    Sally Mustafa, Ridha Joober, Martín Lepage, Srividya N. Iyer, Jai L. Shah, ASHOK K. MALLA · 2018 · Schizophrenia Research
64. Aripiprazole, Ziprasidone, and Quetiapine in the Treatment of First-Episode Nonaffective Psychosis
    Benedicto Crespo‐Facorro, Rocío Pérez‐Iglesias, Ignacio Fernandez Mata, Víctor Ortiz‐García de la Foz, Obdulia Martínez‐García, Elsa M. Valdizán, José Luis Vázquez‐Barquero · 2013 · Journal of Clinical Psychopharmacology
65. First-Episode Psychosis: A Window of Opportunity for Best Practices
    P.F. Buckley, Christoph Ulrich Correll, Alexander L. Miller · 2007 · CNS Spectrums
66. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia
    Wayne Macfadden, Cynthia A. Bossie, Ibrahim Turkoz, J. Thomas Haskins · 2010 · International Clinical Psychopharmacology
67. An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
    Leslie Citrome, Christine E. Graham, Adam Simmons, Ying Jiang, Mark S. Todtenkopf, Bernard L. Silverman, Lauren DiPetrillo, Hannah Cummings, Lei Sun, David McDonnell · 2021 · Neuropsychiatric Disease and Treatment
68. Paliperidone extended‐release tablets in patients with recently diagnosed schizophrenia
    Carla M. Canuso, Cynthia A. Bossie, Joan C. Amatniek, Ibrahim Turkoz, Gahan Pandina, Barbara A. Cornblatt · 2010 · Early Intervention in Psychiatry
69. Effectiveness as an outcome measure for treatment trials in psychiatry
    W. Wolfgang Fleischhacker, Guy M. Goodwin · 2009 · World Psychiatry
70. Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission
    Iris E. Sommer, Franciska de Beer, Shiral S. Gangadin, Lieuwe de Haan, Wim Veling, Nico J.M. van Beveren, Nynke Boonstra, Bram‐Sieben Rosema, Jim van Os, Martijn Kikkert et al. · 2025 · JAMA Psychiatry
71. Schizophrenia Treatment Guidelinesin the United States
    Troy A. Moore · 2011 · Clinical Schizophrenia & Related Psychoses
72. What do large scale studies of medication in schizophrenia add to our management strategies?
    Mark A Agius, Abigail Davis, Michael James Gilhooley, Shelley Chapman, Rashid Zaman · 2010 · PubMed
73. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
    Marcos Gómez‐Revuelta, José María Pelayo‐Terán, María Juncal‐Ruíz, Víctor Ortiz‐García de la Foz, Javier Vázquez-Bourgón, Ana María González-Pinto, Benedicto Crespo‐Facorro · 2018 · The International Journal of Neuropsychopharmacology
74. Eating disturbances in the elderly: A geriatric-psychiatric perspective
    Esra Ateş Bulut, Rita Khoury, Hyun Lee, George Thomas Grossberg · 2019 · Nutrition and Healthy Aging
75. Achieving the lowest effective antipsychotic dose for patients with remitted psychosis: a proposed guided dose-reduction algorithm
    Liu, Chen-Chung, Takeuchi, Hiroyoshi · 2020 · CNS Drugs
76. Classifying Antipsychotic Agents
    Ripu Daman Jindal, Matcheri S. Keshavan · 2008 · CNS Drugs
77. T4 and waist:hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia
    Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He et al. · 2017 · Psychoneuroendocrinology
78. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison
    Benedicto Crespo‐Facorro, Rocío Pérez‐Iglesias, Ignacio Fernandez Mata, Mariluz Ramírez-Bonilla, Obdulia Martínez‐García, Gema Pardo‐García, Olalla Caseiro, José María Pelayo‐Terán, José Luis Vázquez‐Barquero · 2011 · Journal of Psychopharmacology
79. Retracted: Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia
    Tomomi Tenjin, Seiya Miyamoto, Nobumi Miyake, Shin Ogino, Rei Kitajima, Kazuaki Ojima, Jun Arai, 寺本晴樹, Sachiko Tsukahara, Yukie Ito et al. · 2012 · Human Psychopharmacology Clinical and Experimental · Retracted
80. Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness
    Erik Johnsen, Rune A. Kroken · 2012 · Therapeutic Advances in Chronic Disease
81. A Pharmacoeconomic analysis of compliance gains on antipsychotic medications
    Joep Damen, Per-Olof Thuresson, Bart M. S. Heeg, Mickael Löthgren · 2008 · Applied Health Economics and Health Policy
82. Developing a healthy living intervention for people with early psychosis using the Medical Research Council's guidelines on complex interventions: Phase 1 of the HELPER – InterACT programme
    Tim Bradshaw, Alison J. Wearden, Max Marshall, J. Warburton, Nusrat Husain, Rebecca Pedley, Diane Escott, Caroline Swarbrick, Karina Lovell · 2011 · International Journal of Nursing Studies
83. Olanzapine‐induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin
    Francisco Romo‐Nava, Frederik N. Buijs, Marcela Valdés‐Tovar, Gloria Benítez‐King, M. del Carmen Basualdo, Mercedes Perusquı́a, Gerhard Heinze, Carolina Escobar, Ruud M. Buijs · 2017 · Journal of Pineal Research
84. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
    Jyoti Kaushal, Garima Bhutani, Rajiv Gupta · 2012 · PubMed
85. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate
    Jennifer Kern Sliwa, Dong‐Jing Fu, Cynthia A. Bossie, Ibrahim Turkoz, Larry D Alphs · 2014 · BMC Psychiatry
86. Obesity and Mental Illness
    Leslie Citrome, Betty Vreelandb · 2008 · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry
87. Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, “real world” clinical trial
    Cheng Zhang, Yanbo Yuan, Xue Han, Lei Yang, Xin Ying Zeng, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao et al. · 2019 · Psychiatry Research
88. Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain
    Henrik Thyge Corfitsen, Betina Krantz, Agnete Larsen, Antonio Drago · 2019 · Acta Neuropsychiatrica
89. Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
    Ofer Agid, Gary J. Remington, Carmen Fung, Natalie Nightingale, Marc Duclos, Gregory J. Anger · 2021 · The Canadian Journal of Psychiatry
90. Clinical outcomes of long‐acting risperidone in recent versus long‐term diagnosed B elgian schizophrenic patients: results from electronic S chizophrenia T reatment A dherence R egistry ( e ‐ STAR ) and T rial for the I nitiation and M aintenance Of RE mission in S chizophrenia with risperidone ( TIMORES )
    Vincent Dubois, Joseph Peuskens, Paul Geerts, Johan Detraux · 2013 · Early Intervention in Psychiatry
91. Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation
    Chris Bushe, D. McNamara, C. Haley, Mary Fleming McCrossan, Pat Devitt · 2008 · BMC Psychiatry
92. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
    Chen‐Chung Liu, Jia‐Chi Shan, C. Nora Chiang, Ming Hsien Hsieh, Chih‐Min Liu, Yi‐Ling Chien, Shao-Chien Chen, Tzung‐Jeng Hwang · 2013 · Journal of the Formosan Medical Association
93. Antipsychotics and the Dopamine–Serotonin Connection
    B. Ellenbroek, A. Cesura · 2014 · Topics in medicinal chemistry
94. Antipsychotic medications and cognitive functioning in bipolar disorder: moderating effects of COMT Val108/158Met genotype
    Baer M.G. Arts, Claudia J.P. Simons, Marjan Drukker, Jim van Os · 2013 · BMC Psychiatry
95. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective
    A.C. Altamura, D. Armadoros, Matthias Jaeger, R. Kernish, Julie C. Locklear, Hans‐Peter Volz · 2008 · Current Medical Research and Opinion
96. No differences in olanzapine‐ and risperidone‐related weight gain between women and men: a meta‐analysis of short‐ and middle‐term treatment
    Georgios Schoretsanitis, Marjan Drukker, Jim van Os, Koen R.J. Schruers, Maarten Bak · 2018 · Acta Psychiatrica Scandinavica
97. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs , a randomized, open‐label study
    Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun‐ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Sugawara Kikuchi, Toshiaki Shichijo et al. · 2021 · Psychiatry and Clinical Neurosciences
98. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
    Roger S. McIntyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni E. Harris‐White, Sarah C. Akerman · 2022 · CNS Spectrums
99. The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder
    Larry D Alphs, Brianne Brown, Ibrahim Turkoz, Pamela C. Baker, Dong‐Jing Fu, Keith H. Nuechterlein · 2022 · Schizophrenia Research
100. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
     Simon Frey, Roland Linder, Georg Juckel, Tom Stargardt · 2013 · The European Journal of Health Economics